Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasma lipid changes and medroxyprogesterone acetate.

I S Fraser

    Contraceptive Delivery Systems
    |January 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Research and clinical management for women with abnormal uterine bleeding in the reproductive years: More than PALM-COEIN.

    BJOG : an international journal of obstetrics and gynaecology·2016
    Same author

    Inflammation and endometrial bleeding.

    Climacteric : the journal of the International Menopause Society·2014
    Same author

    Dysregulation of vascular endothelial growth factors and their neuropilin receptors in the eutopic endometrium of women with endometriosis.

    Reproductive sciences (Thousand Oaks, Calif.)·2013
    Same author

    Iatrogenic unscheduled (breakthrough) endometrial bleeding.

    Reviews in endocrine & metabolic disorders·2012
    Same author

    Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial.

    Human reproduction (Oxford, England)·2011
    Same author

    Endometrial stromal cells and immune cell populations within lymph nodes in a nonhuman primate model of endometriosis.

    Reproductive sciences (Thousand Oaks, Calif.)·2011
    Same journal

    Premenopausal fertility score as a guide for individual anticonception.

    Contraceptive delivery systems·1984
    Same journal

    Studies on membrane-active vaginal spermicides.

    Contraceptive delivery systems·1984
    Same journal

    Prospective experience with a levonorgestrel implant--Norplant.

    Contraceptive delivery systems·1984
    Same journal

    Different approaches in contraception.

    Contraceptive delivery systems·1984
    Same journal

    Restovar--new low-dose, combined, oral contraceptive. Effects on serum proteins, free testosterone and clinical efficacy.

    Contraceptive delivery systems·1984
    Same journal

    Influence of Exluton (progestogen-only OC) and the Multiload Cu 250 IUD on lactation.

    Contraceptive delivery systems·1984
    See all related articles

    Progestogens, particularly 19-nor testosterone derivatives, can negatively impact lipid metabolism by lowering HDL cholesterol. While risks are small, this effect warrants consideration for cardiovascular disease risk.

    Area of Science:

    • Endocrinology
    • Cardiovascular Science
    • Metabolic Research

    Background:

    • Progestogens significantly influence lipid metabolism, with effects often dose-dependent.
    • 19-nor testosterone derivatives show more pronounced effects on lipid profiles compared to other progestogens.

    Purpose of the Study:

    • To investigate the impact of progestogens on lipid metabolism, focusing on high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C).
    • To assess the potential long-term cardiovascular risks associated with progestogen use, particularly depot medroxyprogesterone acetate (DMPA).

    Main Methods:

    • Review of existing literature on progestogen effects on lipid profiles.
    • Analysis of studies examining changes in HDL-C, LDL-C, and triglycerides associated with progestogen use, including DMPA.
    Keywords:
    BiologyBody WeightContraceptionContraceptive AgentsContraceptive Agents, FemaleContraceptive Agents, ProgestinFamily PlanningLipid Metabolic Effects--analysisLipidsMedroxyprogesterone AcetateMetabolic EffectsPhysiologyReproductive Control AgentsSteroid Metabolic Effects

    Related Experiment Videos

    Main Results:

    • Progestogens suppress HDL-C and increase LDL-C, potentially increasing atherosclerosis risk over time.
    • Depot medroxyprogesterone acetate (DMPA) reduced HDL-C by 15-20% but generally kept levels within the normal range and did not affect triglycerides.
    • Progestogen-induced lipid changes differ from those caused by estrogen or combined estrogen-progestogen therapies.

    Conclusions:

    • While long-term cardiovascular disease risk from DMPA appears small, it may increase with co-existing risk factors.
    • Emerging evidence suggests certain progestogens can significantly lower HDL-C, a marker associated with cardiovascular disease risk, unlike estrogen.
    • The potential for progestogens to contribute to cardiovascular disease warrants further consideration.